PolyPid director granted 9,132 stock options

PolyPid Ltd. director Joseph BenAmram reported a compensation grant of stock options to acquire 9,132 Ordinary Shares.

Accepted by SEC EDGAR 07/17/2026 - 04:02 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

PolyPid Ltd. director Joseph BenAmram reported a compensation grant of stock options to acquire 9,132 Ordinary Shares. The options have an exercise price of $4.46 per share and expire on July 15, 2036. They vest on a quarterly basis beginning July 15, 2026 until April 15, 2030, and this award brings his reported stock option holdings to 9,132 options.

Insider Trade Summary

Grant/Award: 9,132 shares

Grant/Award 1 txn

Insider BenAmram Joseph

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock option (right to buy) F1	9,132	$4.46	$41K

Holdings After Transaction: Stock option (right to buy) — 9,132 contracts (Direct)

Holdings Before and After: Stock option (right to buy), 0 to 9,132 contracts (Direct)

Footnotes (1)

1. F1. The options vest on a quarterly basis beginning July 15, 2026 until April 15, 2030.

Key Figures

Options Granted: 9132.0000 options Exercise Price: $4.4600 per share Underlying Shares: 9132.0000 shares +4 more

7 metrics

Options Granted 9132.0000 options Stock option grant reported by director on 2026-07-15

Exercise Price $4.4600 per share Exercise price for the granted stock options

Underlying Shares 9132.0000 shares Ordinary Shares underlying the granted stock options

Expiration Date 2036-07-15 Expiration date of the granted stock options

Vesting Start 2026-07-15 Quarterly vesting begins on July 15, 2026

Vesting End 2030-04-15 Quarterly vesting continues until April 15, 2030

Holdings After Grant 9132.0000 options Total stock options held by the director following this transaction

Key Terms

Stock option (right to buy), exercise price, vesting, Ordinary Shares

4 terms

Stock option (right to buy) financial

"security_title: Stock option (right to buy)"

exercise price financial

"conversion_or_exercise_price: 4.4600"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"The options vest on a quarterly basis beginning July 15, 2026"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

Ordinary Shares financial

"underlying_security_title: Ordinary Shares"

Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What transaction did PolyPid (PYPD) director Joseph BenAmram report?

Director Joseph BenAmram reported a grant of stock options in PolyPid Ltd. The award covers 9,132 options to purchase Ordinary Shares at an exercise price of $4.46 per share, expiring on July 15, 2036, as director compensation.

How many PolyPid (PYPD) options were granted to director Joseph BenAmram?

Joseph BenAmram was granted 9,132 stock options in PolyPid. Each option relates to one Ordinary Share, giving rights over 9,132 underlying shares. Following this grant, his reported stock option holdings total 9,132 options with no sales disclosed.

What is the exercise price of the stock options granted to PolyPid (PYPD) director Joseph BenAmram?

The granted options have an exercise price of $4.46 per share. This means each option allows purchase of one PolyPid Ordinary Share at $4.46, regardless of future market price, subject to vesting and the stated expiration date of July 15, 2036.

What is the vesting schedule for Joseph BenAmram’s PolyPid (PYPD) stock options?

The options vest on a quarterly basis, beginning July 15, 2026 and continuing until April 15, 2030. This staged vesting means portions of the 9,132 granted options become exercisable over time rather than all at once.

When do the stock options granted to PolyPid (PYPD) director Joseph BenAmram expire?

The granted stock options carry an expiration date of July 15, 2036. After this date, any unexercised options from the 9,132-option award will lapse. The options vest quarterly between July 15, 2026 and April 15, 2030.

Does the PolyPid (PYPD) Form 4 indicate any stock sales by director Joseph BenAmram?

No stock sales are reported; the filing shows only a grant of 9,132 stock options. The transaction is coded as a grant, award, or other acquisition, increasing his reported option holdings to 9,132 options with no dispositions listed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

BenAmram Joseph

(Last) (First) (Middle)

C/O POLYPID LTD.

18 HASIVIM STREET ISRAEL

(Street)

PETACH TIKVA 495376

(City) (State) (Zip)

ISRAEL

(Country)

2. Issuer Name and Ticker or Trading Symbol
PolyPid Ltd. [ PYPD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock option (right to buy)	$4.46	07/15/2026		A		9,132		10/15/2026(1)	07/15/2036	Ordinary Shares	9,132	$4.46	9,132	D

Explanation of Responses:

1. The options vest on a quarterly basis beginning July 15, 2026 until April 15, 2030.

	/s/ BenAmram Joseph	07/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)